Mission Cure Capital (MCC) is the first and only mission-driven impact investment company focused on Pancreatitis. MCH invests in commercially-promising research and development projects that will improve the lives of children and adults suffering from pancreatitis. Pancreatitis is a genetically-driven, debilitating disease that causes inflammation and severe pain and leads to digestive dysfunction, diabetes and an increased risk of pancreatic cancer. Chronic and recurrent acute pancreatitis affects over 600,000 people in the United States alone plus millions more worldwide. There are currently no effective treatments or cures but with clear priorities and our focused investment strategy, we intend to change that.